Prolongation of skin allograft survival in mice treated with CTLA-4 Ig in combination with rapamycin or cyclosporine.
Hale
D A
DA
New England Deaconess Hospital, Boston, Massachusetts 02215, USA.
Gottschalk
R
R
Wood
M L
ML
Maki
T
T
Monaco
A P
AP
D000069594:Abatacept; D000818:Animals; D015703:Antigens, CD; D000943:Antigens, Differentiation / Q000627:therapeutic use*; D060908:CTLA-4 Antigen; D016572:Cyclosporine / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006085:Graft Survival / Q000187:drug effects / Q000276:immunology*; D018796:Immunoconjugates; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D051379:Mice; D008809:Mice, Inbred C3H; D008815:Mice, Inbred Strains; D011090:Polyenes / Q000627:therapeutic use*; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D020123:Sirolimus; D016038:Skin Transplantation / Q000276:immunology*; D013997:Time Factors; D014184:Transplantation, Homologous
D015703:Antigens, CD; D000943:Antigens, Differentiation; D060908:CTLA-4 Antigen; C556707:Ctla4 protein, mouse; D018796:Immunoconjugates; D007166:Immunosuppressive Agents; D011090:Polyenes; D011993:Recombinant Fusion Proteins; D000069594:Abatacept; D016572:Cyclosporine; D020123:Sirolimus